MAHAMAYA LIFESCIEN...● IPO DETAIL GMPNIL STATUSListed IPOCloudTrack Every IPO MAHAMAYA LIFESCIEN...● IPO DETAIL GMPNIL STATUSListed IPOCloudTrack Every IPO
Live GMP
Back to IPOs
ML

Mahamaya Lifesciences Ltd.

BSE SME · SME IPO
Listed BSE SME SME Live Chart
Issue Price
₹114
₹114
GMP (Grey Market)
NIL
Unofficial data only
Est. Listing Price
₹114
Based on GMP
Min. Investment
₹136,800
1 lot × 1200 shares
Subscribed
1.00x
Over-subscribed
IPO Details
Open Date
11 Nov 2025
Close Date
13 Nov 2025
Allotment
14 Nov 2025
Listing Date
18 Nov 2025
Exchange
BSE SME
Price Band
₹114
Listing Price
See chart
Allotment Status
Price Band
₹114
Per share
Face Value
₹10 per share
 
Lot Size
1,200 Shares
per lot
Issue Size
61,78,800 shares (aggregating up to ₹70.44 Cr)
Total offering
Issue Type
Bookbuilding IPO
 
Min Investment
₹136,800
1 lot
Pre-IPO Holding
1,77,66,200 shares
Promoters
Post-IPO Holding
2,34,05,000 shares
Promoters
P/E (Pre)
15.65x
 
P/E (Post)
16.25x
 
EPS (Pre)
₹7.29
 
EPS (Post)
₹7.01
 
UPI Deadline
2025-11-13
Mandate
Anchor AllotmentMon, 10 Nov 2025
Basis of AllotmentFri, 14 Nov 2025
Refund InitiationMon, 17 Nov 2025
Demat CreditMon, 17 Nov 2025
Listing DayTue, 18 Nov 2025
UPI Mandate Deadline2025-11-13
Sale TypeFresh Capital-cum-Offer for Sale
Net Offer to Public58,69,200 shares (aggregating up to ₹66.91 Cr)
Market Maker Quota3,09,600 shares (aggregating up to ₹3.53 Cr)
Fresh Issue Shares53,29,200 shares (aggregating up to ₹60.75 Cr)
Offer for Sale5,40,000 shares of ₹10 (aggregating up to ₹6.16 Cr)
QIB Quota50% of Net Issue
HNI / NII Quota15% of Net Issue
Retail Quota35% of Net Issue
Check AllotmentClick here →
Subscription Rate Final
Mahamaya Lifesciences Ltd. IPO subscribed 1.00 times overall. Retail: 1.00x. QIB: 1.00x. NII: 1.00x. By 13 Nov 2025.
QIB
1.00x
Over
NII/HNI
1.00x
Over
Retail
1.00x
Over
Total
1.00x
Over
Category Subscription Shares Offered % of Total Amount (₹Cr)
Market Maker
Awaited
309,600
₹3.53
QIB
Over 1.00x
NII / HNI
Over 1.00x
Retail
Over 1.00x
Total 1.00x
6,178,800
100% ₹70.44
IPO Shares Offered
Mahamaya Lifesciences Ltd. IPO total issue size: ₹70.44 Cr.
CategoryShares OfferedAmount (₹Cr)Size (%)
Market Maker 309,600 ₹3.53
5.01%
Total 6,178,800 ₹70.44
100.00%
* Based on upper price band ₹114 per share
Lot Size & Investment
Lot Size
1,200
Shares per Lot
Issue Price
₹114.00
Upper Band
Min Investment
₹136,800
1 Lot
ApplicationLotsSharesAmount
Retail (Min — 2 Lots)22,400₹273,600
Retail (Max — 13 Lots)1315,600₹1,778,400
S-HNI (Min — 14 Lots)1416,800₹1,915,200
B-HNI (Min — 68 Lots)6881,600₹9,302,400
* Issue Price ₹114 × Lot Size 1,200 shares
IPO Schedule
Anchor
10 Nov 2025
✓ Done
IPO Open
11 Nov 2025
✓ Done
IPO Close
13 Nov 2025
✓ Done
Allotment
14 Nov 2025
✓ Done
Refunds
17 Nov 2025
✓ Done
Demat Credit
17 Nov 2025
✓ Done
Listing Day
18 Nov 2025
✓ Done
Mahamaya Lifesciences Ltd. — Live Price LIVE
₹114.00
INR · BSE
Fetching…
vs Issue Price
OPEN
HIGH
LOW
MKT CAP
P/E
52W HIGH
52W LOW
VOLUME
DIVIDEND
DIV YIELD
Loading…
Chart Not Available
Try again 2–3 days after listing.
Issue ₹114.00 Live Price
About Mahamaya Lifesciences Ltd.
Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management and to help the farming community for more productivity.The company specializes in manufacturing pesticide formulations and supplying bulk products to Indian agrochemical companies and multinational corporations (MNCs).The company imports carefully researched molecules, registers them with the Central Insecticides Board, and markets them as technical and value-added formulations for domestic manufacturers and multinational corporations (MNCs).The company has invested in global product registrations, with active markets in countries like the Dominican Republic, Egypt, Ethiopia, Jordan, UAE, and Turkey, offering high-quality products and data support for registrations.Product Portfolio:Bulk Formulations Sales: Acetamiprid, SP Buprofezin, SC Emamectin benzoate, SG Imidacloprid, SC Paraquat Dichloride.Technical Sales: Acetamiprid Technical 99% Min, Atrazine Technical 95% Min, Imidacloprid Technical 95% Min, Emamectin Benzoate Technical 95% Min.Branded Sales (Major own branded products): MAYAMRIT GR, MAYAMRIT SL, MAYAGIBB, UCHIT EW 370Export Sales- Formulations: Wiper (Sulphur 80% WDG), Lancha (Pendimethalin 50% EC), Tolfen (Tolfenpyrad 15% EC), Typic (80% Sulphur WG).Competitive Strengths:Experienced management team consisting of experts.Capability to introduce vital products for Indian Agriculture.Development of export opportunities of products.Ability to develop brands.Cordial relationships with suppliers of raw materials.Core values focused on achieving sustainability through innovative approaches.
Objects of the Issue
1
1 Purchase of Equipment for existing Formulation plant
2
2 Funding capital expenditure towards setting up of a new technical manufacturing plant
3
3 Construction of Warehouse Building and Purchase of Machinery
4
4 Funding working capital requirement of our Company
5
5 General Corporate purposes
Mahamaya Lifesciences Ltd. Financials (Amount in ₹ Crore)
Revenue from Operations
₹162.8
31 Mar 2024
₹267.2
31 Mar 2025
₹84.0
30 Jun 2025
Profit After Tax (PAT)
₹5.2
31 Mar 2024
₹12.9
31 Mar 2025
₹4.1
30 Jun 2025
Particulars30 Jun 202531 Mar 202531 Mar 2024
Revenue from Operations 84.04 267.17 162.83
EBITDA 8.04 24.64 13.36
Profit After Tax (PAT) 4.10 12.94 5.22
Net Worth 53.50 49.42 24.66
Total Assets 218.87 188.35 112.07
Reserves & Surplus 35.73 31.66 23.41
Borrowings 57.72 58.11 54.63
EBITDA Margin (%) 9.22%
PAT Margin (%) 4.84%
P/BV Ratio
9.40
RoE
34.94%
RoCE
23.15%
RoNW
26.19%
PAT Margin
4.84%
EBITDA Margin
9.22%
Debt/Equity
1.08
Issue Structure & Shareholding
Total Shares Offered61,78,800 (100.00%)
Net Offer to Public58,69,200 shares (aggregating up to ₹66.91 Cr)
Reserved for Market Maker3,09,600 shares (aggregating up to ₹3.53 Cr)
Pre-Issue Promoter Holding1,77,66,200 shares
Post-Issue Promoter Holding2,34,05,000 shares
P/BV Ratio9.40
RoE34.94%
RoCE23.15%
Debt / Equity1.08
Script CodeN/A
Registrar & Lead Managers
Book Running Lead Managers
Oneview Corporate Advisors Pvt.Ltd.
GMP Disclaimer: Grey Market Premium data is unofficial and unregulated. It does not guarantee actual listing price.
IPO Subscription FAQs
How much Mahamaya Lifesciences Ltd. IPO subscribed?

Mahamaya Lifesciences Ltd. IPO is subscribed 1.00 times by Nov 13, 2025. Retail: 1.00x. QIB: 1.00x. NII: 1.00x.

Investor CategorySubscription
Qualified Institutional (QIB)1.00x
Non Institutional (NII/HNI)1.00x
Retail Individual1.00x
Total Subscription1.00x
What is Mahamaya Lifesciences Ltd. IPO retail subscription status?

The Mahamaya Lifesciences Ltd. IPO retail category is subscribed 1.00 times as of 13 Nov 2025. The retail portion is oversubscribed.

How to subscribe Mahamaya Lifesciences Ltd. IPO?

Subscribe via your broker app using ASBA or UPI. Opens 11 Nov 2025 and closes 13 Nov 2025. Min investment: ₹136,800 (1 lot = 1,200 shares). UPI mandate: 2025-11-13.

How many times Mahamaya Lifesciences Ltd. IPO subscribed?

The Mahamaya Lifesciences Ltd. IPO subscribed 1.00x overall. QIB: 1.00x, NII: 1.00x, Retail: 1.00x. Applications: from NSE/BSE.

How to check Mahamaya Lifesciences Ltd. IPO allotment?

Check allotment on the registrar website (Kfin Technologies Ltd.) at https://ipostatus.kfintech.com/. Enter your PAN, application number or DP/Client ID. Allotment date: 14 Nov 2025. Refunds: on 17 Nov 2025.

When Mahamaya Lifesciences Ltd. IPO will be listed?

The Mahamaya Lifesciences Ltd. IPO listing date is 18 Nov 2025, Tuesday. Listed on: BSE SME. Issue price: ₹114. Estimated listing: ₹114. GMP: NIL.

When Mahamaya Lifesciences Ltd. IPO close?

The Mahamaya Lifesciences Ltd. IPO closes on 13 Nov 2025, Thursday. UPI mandate: 2025-11-13. Allotment: 14 Nov 2025. Listing: 18 Nov 2025.